QDEL

QuidelOrtho Corp

Add to Watchlist

Advanced Chart

23.910

-0.49(-2.008%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.455

Open

24.400

VWAP

23.97

Vol

1.06M

Mkt Cap

1.62B

Low

23.700

Amount

25.36M

EV/EBITDA(TTM)

7.32

Total Shares

66.97M

4.11B

EV/OCF(TTM)

20.52

P/S(TTM)

0.60

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

672.51M

-7.51%

0.523

-38.5%

729.59M

+3.08%

0.974

+54.53%

715.81M

+3.32%

0.894

+20.75%

Estimates Revision

The market is revising Upward the revenue expectations for QuidelOrtho Corporation (QDEL) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -34.20%.

Revenue Estimates for FY2025

Revise Upward

+0.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.9%

In Past 3 Month

Stock Price

Go Down

-34.20%

In Past 3 Month

8 Analyst Rating

85.24% Upside

Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 44.29 USD with a low forecast of 27.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

1 Sell

Moderate Buy

85.24% Upside

Current: 23.910

Low

27.00

Averages

44.29

High

60.00

85.24% Upside

Current: 23.910

Low

27.00

Averages

44.29

High

60.00

Citi

Buy

downgrade

$50 -> $40

2025-08-06

New

Reason

Citi

Price Target

$50 -> $40

2025-08-06

New

downgrade

Buy

Reason

Citi lowered the firm's price target on QuidelOrtho to $40 from $50 and keeps a Buy rating on the shares. The firm views the company's Q2 report and cost actions planned for the back of half of 2025 positively.

Raymond James

Outperform

maintain

$60 -> $55

2025-08-06

New

Reason

Raymond James

Price Target

$60 -> $55

2025-08-06

New

maintain

Outperform

Reason

Raymond James lowered the firm's price target on QuidelOrtho to $55 from $60 and keeps an Outperform rating on the shares. QuidelOrtho reported a strong and "fairly clean" quarter, with revenues roughly in line with estimates, outperformance in Labs, and relatively in-line respiratory revenues, the analyst tells investors in a research note. Raymond James views the updated guidance as prudent given the "show me" nature of the story.

Nephron Research

Buy -> Hold

downgrade

$40

2025-07-09

Reason

Nephron Research

Price Target

$40

2025-07-09

downgrade

Buy -> Hold

Reason

Nephron Research downgraded QuidelOrtho to Hold from Buy with a $40 price target.

UBS

Neutral

downgrade

$45 -> $29

2025-05-08

Reason

UBS

Price Target

$45 -> $29

2025-05-08

downgrade

Neutral

Reason

UBS lowered the firm's price target on QuidelOrtho to $29 from $45 and keeps a Neutral rating on the shares. Margins are on track and guidance was reaffirmed amid a smaller-than-expected impact from tariffs, the analyst tells investors in a research note.

Jefferies

Tycho Peterson

Hold

Buy

upgrade

$44

2025-05-08

Reason

Jefferies

Tycho Peterson

Price Target

$44

2025-05-08

upgrade

Hold

Buy

Reason

Jefferies analyst Tycho Peterson upgraded QuidelOrtho to Buy from Hold with a $44 price target.

Jefferies

Hold

Buy

upgrade

$44

2025-05-08

Reason

Jefferies

Price Target

$44

2025-05-08

upgrade

Hold

Buy

Reason

As previously reported, Jefferies upgraded QuidelOrtho to Buy from Hold with a $44 price target. The Q1 report highlighted improving EBITDA margins and the ability to fully mitigate tariffs, notes the analyst, who says that in the case of QuidelOrtho's guidance being maintained with no tariff impact that "no news is good news." Valuation has moved lower and the firm sees early signs of a turnaround under CEO Brian Blaser, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for QuidelOrtho Corp (QDEL.O) is 8.87, compared to its 5-year average forward P/E of 15.59. For a more detailed relative valuation and DCF analysis to assess QuidelOrtho Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

15.59

Current PE

8.87

Overvalued PE

21.98

Undervalued PE

9.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

8.24

Current EV/EBITDA

6.83

Overvalued EV/EBITDA

10.86

Undervalued EV/EBITDA

5.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

2.40

Current PS

0.60

Overvalued PS

4.10

Undervalued PS

0.71